Tag: GlobeNewswire

Agreement brings together RAYEL’s scientific foundation, KRTL’s U.S. commercialization strategy and expanding regulatory, API and research capabilities

Lakewood, CO, Oct. 05, 2026 (GLOBE NEWSWIRE) — KRTL Holding Group Inc. (OTC: KRTL) (“KRTL” or the “Company”) today announced that its wholly owned subsidiaries, KRTL International Corp. and KRTL Biotech Inc., have executed a definitive strategic partnership agreement with CENTRO DE INVESTIGACIONES QUIMICAS, S.R.L. (“CIQ”) for the continued development and commercialization of the RAYEL platform.

The agreement marks an important transition for RAYEL. What began under a Memorandum of Understanding now moves into a binding framework designed to support U.S. commercialization, manufacturing evaluation, strategic partnerships, regulatory coordination, capital development and additional potential applications for the platform.

For KRTL, the timing is significant. The Company has been building the pieces around RAYEL – strengthening its U.S. regulatory and pharmaceutical/API capabilities, organizing the platform’s technical and commercial record, developing potential partner pathways and opening discussions with universities regarding potential research collaboration.

KRTL Holding Group management stated: “This agreement brings together work that has been developing on several fronts. We have CIQ’s scientific and technical foundation, a defined U.S. commercialization strategy, growing regulatory and API expertise through KRTL Biotech, and active discussions with universities. We can now begin bringing those pieces together around RAYEL and evaluating where the platform has the strongest opportunity to advance.”

The Platform and the Path

Under the agreement, KRTL will lead the U.S. commercialization pathway for RAYEL, while CIQ continues its scientific and technical role. The parties will coordinate strategy and make material project decisions together.

KRTL and CIQ are evaluating multiple potential uses and commercial pathways for RAYEL.

The platform has a documented beverage-facing TTB pathway for its documented product scope, while the parties are also evaluating how RAYEL could be developed across additional pharmaceutical/API-oriented and other potential applications.

Rather than building RAYEL around a single prospective market, KRTL intends to evaluate where the platform, its scientific record and future research may have the strongest commercial fit.

The Opportunity Around RAYEL

That strategy is taking shape against a growing global market for plant-derived extracts.

MarketsandMarkets estimates the global plant extracts market at approximately $47.54 billion in 2025 and projects it to reach $85.28 billion by 2030, representing a 12.4% compound annual growth rate. The market spans applications including food and beverages, pharmaceuticals, dietary supplements and cosmetics. Source: MarketsandMarkets

KRTL has been working to build the capabilities needed to evaluate RAYEL within that broader environment.

Through KRTL Biotech, the Company engaged Justin Abril as President-Designate and Strategic Regulatory & API Consultant, adding experience in regulatory strategy, pharmaceutical/API development planning, API/CMC documentation, controlled-substance compliance planning, import/export pathway review and partner diligence.

KRTL is also in active discussions with universities regarding potential research collaboration related to RAYEL, creating another potential avenue for scientific and technical development around the platform.

Put together, the strategy is becoming clearer: CIQ provides the scientific and technical foundation; KRTL is building the commercial, regulatory, research and partner-development infrastructure around it; and the definitive agreement provides the framework for those efforts to move forward together.

What Comes Next

The focus now turns to translating that framework into qualified opportunities.

KRTL and CIQ will continue developing the RAYEL technical and commercial record while evaluating research, manufacturing, strategic and commercial relationships in the United States. As individual opportunities mature, they can move into project-specific agreements appropriate to the particular pathway.

KRTL management added: “Signing the agreement is a milestone, but what matters now is what we build from it. Our focus is getting RAYEL in front of the right researchers, technical groups, manufacturers and commercial partners and allowing the science, the documentation and the market opportunity to guide where we go next.”

Any regulated manufacturing, controlled-substance handling, testing, importation, formulation, pharmaceutical/API development or distribution would be performed through appropriately qualified and authorized external parties.

About KRTL Holding Group Inc.

KRTL Holding Group Inc. (OTC: KRTL) operates through specialized subsidiaries focused on life sciences, international project development, healthcare and related emerging commercial opportunities.

KRTL Biotech Inc. supports life-sciences platform development, regulatory and pharmaceutical strategy, partner coordination and commercialization. KRTL International Corp. serves as the Group’s international, federal-facing and cross-border project-development and partnering platform.

KRTL Holding Group: www.krtlholding.com
KRTL International: www.krtl-icc.com
Contact: info@krtlholding.com

Forward-Looking Statements

This press release contains forward-looking statements regarding RAYEL development, potential university and research collaborations, commercialization, manufacturing evaluation, pharmaceutical/API-oriented and other potential applications, strategic partnerships, regulatory pathways, financing and future commercial opportunities. Such statements involve risks and uncertainties, and actual results may differ materially from those expressed or implied.

RAYEL remains subject to technical validation, documentation, partner and institutional diligence, financing considerations, applicable regulatory requirements and future agreements. Evaluation of pharmaceutical/API-oriented, alkaloid-related, whole-extract or other regulated pathways does not mean that RAYEL has been approved or authorized for those uses. Any regulated activities would require the applicable licenses, registrations, approvals and appropriately qualified external parties.

The plant-extract market figures referenced above are third-party industry estimates from MarketsandMarkets and describe the broader global plant-extract industry. They are not estimates of RAYEL’s addressable market, future revenues, valuation or expected market share.

Discussions with universities and other prospective research, manufacturing, strategic or commercial partners remain subject to further diligence and definitive agreements where applicable. The execution of the CIQ agreement does not represent FDA approval, DEA authorization, secured financing or commercial launch.

CONTACT: www.krtlholding.com
info@krtlholding.com

Contact: 855-KRTL-HLD

www.krtlbiotech.com
info@krtlbiotech.com

www.krtl-icc.com
info@krtl-icc.com

VANCOUVER, British Columbia, Oct. 05, 2026 (GLOBE NEWSWIRE) — AnorTech Inc. (“AnorTech” or the “Company”) (TSX Venture Exchange “ANOR”; OTCQB “ANORF”) is pleased to announce that Greenland Mines Ltd. (“Greenland Mines”) (Nasdaq: GRML) has exercised in full its option under the share exchange agreement between the two companies (the “Agreement”) (see NR2026-04) to acquire an additional 25,168,669 common shares of AnorTech (the “AnorTech Shares”) at a deemed price of C$0.30 per share (the “Transaction”). On closing of the Transaction (“Closing”), Greenland Mines’ ownership will double from approximately 9.9% to approximately 19.9% of AnorTech’s issued and outstanding common shares, establishing Greenland Mines as a major strategic shareholder.

In exchange for the AnorTech Shares, Greenland Mines will issue common shares with a deemed value of approximately US$5,298,000 (C$7,550,600) of its common shares (the “Greenland Mines Shares”) to AnorTech giving AnorTech a meaningful position in a Nasdaq-listed company and increased access to US markets. The exact number of the Greenland Mines Shares will be based on the 10-day volume-weighted average trading price ending immediately before Closing of Greenland Mines’ common shares on Nasdaq at the time of closing.

Jim Cambon, President of AnorTech, commented:

“Greenland Mines’ decision to exercise its option in full is a strong endorsement of what we are building at AnorTech. Greenland Mines understands the value we are creating from Greenland anorthosite and its exciting future as a key component in the aluminum critical mineral supply chain and as the primary material for lunar project development. We are moving our smelter grade alumina and high purity aluminum technologies towards commercialization while continuing to advance our anorthosite lunar applications with successful test programs on both 3D-printable and refractory cements. We are working with a number of groups in the space industry who are using our anorthosite as a lunar simulant and we expect this sector to grow as lunar programs ramp up. We look forward to maximizing the synergies between our companies and working with Greenland Mines as a strategic shareholder as we advance our lunar materials, smelter grade alumina and high purity alumina programs.”

Bo Møller Stensgaard, President of Greenland Mines, commented:

“In June we said this investment was about moving into the midstream of the critical-materials value chain. Since then, it has become clear that AnorTech’s anorthosite is also relevant to a value chain that is about to grow significantly — the industrial supply chain of the Moon. The lunar highlands, where future space missions are planned to land, are comprised largely of anorthosite. Every landing pad, habitat wall, radiation shield and tonne of aluminum that will one day be produced from lunar regolith starts with the same rock AnorTech is developing at Gronne Bjerg.

Doubling our position gives Greenland Mines shareholders exposure to zero-waste smelter grade alumina and high purity alumina on Earth and to the materials science of building the Moon with the Moon itself. Aluminum is designated as a critical metal in the United States and Canada and AnorTech’s alumina could support both the aluminum smelters in the United States and semiconductor manufacturers who require high purity alumina. Greenland’s strategic importance to the United States and its allies was underscored by the security agreement signed by the United States, Denmark and Greenland on September 22, 2026; we believe AnorTech’s anorthosite is strategically important a great deal further from home too.”

Transaction Terms

The option to increase Greenland Mines’ ownership of AnorTech to 19.9% was granted under the share exchange agreement between Greenland Mines and AnorTech dated June 15, 2026 and announced on June 16, 2026. Under that agreement, Greenland Mines acquired its initial 19,958,503 AnorTech shares, and AnorTech announced completion of that transaction on June 30, 2026. On Closing, Greenland Mines will hold 45,127,172 AnorTech shares representing approximately 19.9% of AnorTech’s issued and outstanding share capital. The AnorTech Shares will be subject to a contractual lock-up period of 60 months from the date of issuance.

The Greenland Mines Shares issued to AnorTech will be subject to a contractual lock-up period as to one-half of the Greenland Mines Shares for 12 months from Closing and a contractual lock-up period as to the remaining one-half of the Greenland Mines Shares for 24 months from Closing. AnorTech currently owns 318,000 shares of Greenland Mines from previous transactions (see NR2026-04 and NR2026-06).

Closing is subject to customary closing conditions, including acceptance by the TSX Venture Exchange (the “TSXV”). No finder’s fee is being paid in connection with the Transaction.

About Greenland Mines

Greenland Mines Ltd. is a Nasdaq-listed resource development and mining company focused on the development of the Skaergaard Project in southeast Greenland and the Sarfartoq neodymium-praseodymium rare earths project in southwest Greenland. Greenland Mines’ strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and select midstream processing opportunities, while advancing its assets and broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure. Greenland Mines has working capital of approximately C$100 million.

About AnorTech Inc.

AnorTech is pioneering the next generation of sustainable materials from anorthosite with over 12 years experience in developing anorthosite products and 25 years experience exploring, building and operating projects in Greenland. The Company owns 100% of the Gronne Bjerg anorthosite project in Greenland which is strategically located just 80km northeast of Nuuk, the capital of Greenland, on open tidewater, a deep-water port location and adjacent to significant hydroelectric potential.

AnorTech is advancing multiple product lines towards commercialization, including:

• Zero-waste Smelter Grade Alumina (SGA) and High Purity Alumina (HPA)
• Next generation alumina-based catalysts for CO2 capture
• CO2-free refractory cement and advanced 3D-printable cement
• Lunar construction materials using anorthosite-based concrete

The Company filed a U.S. provisional patent in 2025 to protect its proprietary sustainable SGA and HPA process (see NR2025-01) and shipped 15 tonnes of Gronne Bjerg anorthosite to Ontario in preparation for pilot plant testing. AnorTech is actively pursuing strategic industry partnerships to accelerate commercialization. AnorTech has over C$3 million in working capital.

ON BEHALF OF THE BOARD OF DIRECTORS

“Jim Cambon”

President and Director

For further information:
Ph: 778-373-2164
www.anortechinc.com

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release contains statements that, to the extent they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. The Company uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend” and similar expressions to identify forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements regarding: the completion of the Transaction and receipt of necessary regulatory approvals, including TSXV approval; the issuance of the AnorTech Shares and the Greenland Mines Shares; expected benefits of the strategic relationship between AnorTech and Greenland Mines; and Greenland Mines’ development of its multi-asset platform and the North Atlantic Critical Metals Corridor. Such forward-looking statements are based on a number of assumptions of management, including, without limitation: that the Transaction will complete as currently planned on the anticipated timeline; that the Company will be able to obtain any necessary third party and regulatory approvals required for the Transaction, including TSXV approval; that each Mines will satisfy the remaining conditions to Closing; that the strategic relationship will provide both parties with the expected benefits; and that market conditions will remain favorable for critical metals projects and alumina technologies. Many factors could cause the Company’s actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things: adverse market conditions; general economic, market or business risks; unanticipated costs; the failure of the Company to obtain any necessary regulatory approvals for the Transaction, including TSXV approval; the failure of either party to satisfy the remaining conditions to Closing; the failure by either or both parties to realize the expected benefits of the strategic relationship; changes in demand for critical minerals or alumina; and the risks and uncertainties described in the Company’s most recent Management’s Discussion & Analysis for the interim period ended June 30, 2026, which can be accessed at the Company’s profile on www.sedarplus.com. This list is not exhaustive of the factors that may affect any of the Company’s forward-looking statements. These and other factors should be considered carefully and accordingly, readers should not place undue reliance on forward-looking information. The “forward-looking statements” contained herein speak only as of the date of this news release and, unless required by applicable law, the Company undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) — Taboola (Nasdaq: TBLA), a global leader in delivering performance at scale for advertisers, today announced a new report, The Data Advantage, highlighting significant shifts and challenges that today’s advertisers face when running campaigns.

Today’s advertisers are faced with a fragmented consumer journey that stretches across devices, channels, with a single purchase decision running across mail, news, search, price aggregators, and increasingly LLMs. U.S. adults spend nearly 13 hours a day with media, on the way to purchase.

The Data Advantage reveals insights about how advertisers are approaching this shift. Key findings include:

• Advertiser budgets are rising nearly 10% in the quest to reach new audiences, with 30% citing new audiences as a top priority for additional budget allocation.
• Despite this objective, an overwhelming majority (81%) of advertisers are failing to reach new audiences and instead rely on repeatedly targeting the same audience segments, however.
• Advertisers say identity fragmentation across pre-conversion touchpoints forces them back into recycled audience pools. 75% of advertisers face difficulty in recognizing the same non-converting customer across multiple touchpoints.
• Advertisers want to diversify spending beyond walled gardens, with 81% open to increasing ad spend across channels like publishers and news sites, if identity challenges are solved.

“As customer journeys become increasingly fragmented, brands and agencies must understand true purchase intent at the crucial moment of choice,” said Adam Singolda, CEO at Taboola. “Outside closed ecosystems, advertisers face a significant identity blind spot, and by relying on recycled audiences on walled gardens, they miss many opportunities. Unlocking identity and measurement on the open web allows brands to break free from targeting ruts and connect with valuable, untapped audiences.”

The Data Advantage surveyed more than 300 senior marketing and advertising leaders working for companies with more than 1,000 employees and a monthly marketing spend of $300,000 or more.

About Taboola
Taboola empowers businesses to grow through performance advertising technology that goes beyond search and social and delivers measurable outcomes at scale.

Taboola works with thousands of businesses who advertise directly on Realize, Taboola’s powerful ad platform, reaching over 600M daily active users across some of the best publishers in the world. Publishers like NBC News and Yahoo, and OEMs such as Samsung, Xiaomi and others use Taboola’s technology to grow audience and revenue, enabling Realize to offer unique data, specialized algorithms, and unmatched scale.

Disclaimer – Forward-Looking Statements
Taboola (the “Company”) may, in this communication, make certain statements that are not historical facts and relate to analysis or other information which are based on forecasts or future or results. Examples of such forward-looking statements include, but are not limited to, statements regarding future prospects, product development and business strategies. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements but are not the exclusive means for identifying such statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and there are risks that the predictions, forecasts, projections and other forward-looking statements will not be achieved. You should understand that a number of factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements, including the risks set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 under Part 1, Item 1A “Risk Factors” and our subsequent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

CONTACT: Contact
Dave Struzzi
Dave.s@taboola.com

ROSEVILLE, Minn., Oct. 05, 2026 (GLOBE NEWSWIRE) — Hawkins, Inc. (Nasdaq: HWKN) announced today that it expects to release its financial results for its second quarter fiscal 2027 ended September 27, 2026 after the market closes on October 26, 2026 at approximately 4:10 p.m. Eastern Time. 

About Hawkins, Inc.

Hawkins, Inc. was founded in 1938 and is a leading water treatment and specialty ingredients company that formulates, manufactures, distributes, and blends products for its Water Treatment, Food & Health Sciences and Industrial Solutions customers. Headquartered in Roseville, Minnesota, the Company has 69 facilities in 28 states and creates value for its customers through superb customer service and support, quality products and personalized applications. Hawkins, Inc. generated approximately $1.1 billion of revenue in fiscal 2026 and has approximately 1,200 employees. For more information, including registering to receive email alerts, please visit www.hawkinsinc.com/investors.

Contact:   Jack Shufelt        
                Investor Relations, Mergers and Acquisitions and Treasury Director
                612/617-8582                
                ir@hawkinsinc.com
                jack.shufelt@hawkinsinc.com

ATHENS, Greece, Oct. 05, 2026 (GLOBE NEWSWIRE) — TEN Ltd. (NYSE: TEN) (“TEN” or the “Company”), a leading diversified tanker and LNG operator, today announced that its Board of Directors declared the regular quarterly cash dividend of approximately $0.59375 per share for its Series F Cumulative Redeemable Perpetual Preferred Shares (the “Series F Preferred Shares”; NYSE: TENPRF).

The dividend on the Series F Preferred Shares is for the period from the most recent dividend payment date on July 30, 2026, through October 29, 2026.

The dividend on the Series F Preferred Shares will be paid on October 30, 2026, to all holders of record of Series F Preferred Shares as of October 27, 2026. Dividends on the Series F Preferred Shares are payable quarterly in arrears on the 30^th day (unless the 30^th falls on a weekend or public holiday, in which case the payment date is moved to the next business day) of January, April, July and October of each year, when, as and if declared by TEN’s board of directors. This is the 33^rd dividend on the Series F Preferred Shares since their commencement of trading on the New York Stock Exchange.

TEN has 6,747,147 Series F Preferred Shares outstanding as of the date of this press release.

ABOUT TEN Ltd.
Founded in Bermuda in 1993 and celebrating 33 years as a public company, 24 of which on the NYSE, TEN is one of the first and most established public shipping companies in the world. TEN’s diversified pro-forma energy fleet currently consists of 80 vessels, totaling approx. 10.4 million dwt.

ABOUT FORWARD-LOOKING STATEMENTS
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. TEN undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For further information, please contact:

Company
Tsakos Energy Navigation Ltd.
George Saroglou
President & COO
+30210 94 07 710
gsaroglou@tenn.gr

Investor Relations / Media
Capital Link, Inc.
Nicolas Bornozis
Markella Kara
+212 661 7566
ten@capitallink.com

NESS ZIONA, Israel, Oct. 05, 2026 (GLOBE NEWSWIRE) — Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in 3D perception systems, today announced that Eli Yoresh, the Company’s Chief Financial Officer, and Oren Bar-On, co-Chief Executive Officer of Foresight Automotive Ltd., will present at the LD Micro 20^th Annual Main Event Conference in Los Angeles, California on Tuesday, October 20, 2026, at 9:00 a.m. PT.

Management will be available on-site for one-on-one meetings. To schedule a meeting, please contact LD Micro or Miri Segal at msegal@ms-ir.com.

A webcast of the presentation will be streamed live at the following link: https://ldmicroevents.com/.

About Foresight

Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) is a technology company developing advanced three-dimensional perception systems and cellular-based applications. Through its wholly owned subsidiaries, Foresight Automotive Ltd., Foresight Changzhou Automotive Ltd. and Eye-Net Mobile Ltd., Foresight develops both “in-line-of-sight” vision systems and “beyond-line-of sight” accident-prevention solutions. Foresight’s 3D perception systems include modules of automatic calibration and dense 3D point cloud that can be applied to different markets such as automotive, defense, autonomous driving, agriculture, heavy industrial equipment and unmanned aerial vehicles. Eye-Net Mobile develops next-generation vehicle-to-everything collision prevention solutions and smart automotive systems to enhance road safety and situational awareness for all road users in urban mobility environments. By leveraging cutting-edge artificial intelligence technology, advanced analytics, and existing cellular networks, Eye-Net’s innovative solution suite delivers real-time pre-collision alerts to all road users via smartphones and other smart devices within vehicles. For more information about Foresight and its wholly owned subsidiary, Foresight Automotive, visit www.foresightauto.com, follow @ForesightAuto1 on X, or join Foresight Automotive on LinkedIn.

About the LD Micro Main Event

The LD Micro 20th Annual Main Event will take place on October 19-21, 2026 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. Registration begins at 2:00 PM PT on Monday, October 19, 2026, followed by keynote programming and a networking reception.

Company presentations will run from 9:00 a.m. PT to 4:00 p.m. PT on Tuesday, October 20 and Wednesday, October 21, 2026. The event will feature more than 100 public companies presenting to and participating in private meetings with investors. Wednesday’s program will conclude with the LD Micro Moneyball Afterparty.

LD Micro, a wholly owned subsidiary of Freedom U.S. Markets, LLC, was founded in 2006 with the sole purpose of being an independent resource in the micro-cap space. Through its dynamic, investor-driven conferences and curated company exposure, LD Micro has served as an invaluable asset to all those interested in discovering the next generation of great companies. For more information on LD Micro, visit www.ldmicro.com.

Investor Relations Contact:
Miri Segal-Scharia
CEO
MS-IR LLC
msegal@ms-ir.com

The Phase 1/2 ABILITY-1 Clinical Trial is evaluating MDNA11 in expansion cohorts comprised of patients with advanced and metastatic gastrointestinal, endometrial, and melanoma cancers

Selected as one of the Top 150 Abstracts at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting

TORONTO and HOUSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune disease, today announced that an abstract reporting topline data from the Phase 1/2 study of MDNA11 has been selected for oral presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.

Details of the oral presentation are as follows:
Abstract Number: 517
Presentation Type: Oral Presentation
Presentation Date: Saturday, November 7, 2026
Presentation Time: 4:30-4:45 p.m. MST
Session: Oral Session 3, 3:30-4:50 p.m. MST
Location: Phoenix Convention Center, Room 301D, Phoenix, Arizona

Title: “MDNA11 Demonstrates Clinical Activity as Monotherapy and in Combination with Pembrolizumab in Biomarker-Enriched Gastrointestinal Malignancies, Including ICI-Refractory Disease.”

About Medicenna Therapeutics
Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer. The Company’s most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. Bizaxofusp has received Fast Track designation from the FDA and Orphan Drug designation in the United States and Europe. Medicenna is also advancing MDNA11, a long-acting IL-2 Superkine designed to selectively activate cancer-fighting immune cells, which is currently being evaluated in the Phase 1/2 ABILITY-1 study and the Phase 1b NEO-CYT study. The Company is also developing MDNA113, a targeted PD-1 x IL-2 bifunctional immunotherapy for solid tumors, and MDNA209, an antagonist of CD122 blocking IL-2/IL-15 signaling, using its proprietary BiSKIT and T-MASK platforms.

For more information, please visit www.medicenna.com, and follow us on X and LinkedIn.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, express or implied statements regarding the future operations of the Company, estimates, plans, strategic ambitions, partnership activities and opportunities, objectives, expectations, opinions, forecasts, projections, guidance, outlook or other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expect”, “believe”, “seek”, “potentially” and similar expressions. and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed in the latest annual information form of the Company and in other filings made by the Company with the applicable securities regulators from time to time in Canada.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.

This news release contains hyperlinks to information that is not deemed to be incorporated by reference in this new release.

Investor and Company Contact
Daniel Scarr
Director, Corporate Development
Medicenna Therapeutics
ir@medicenna.com 

CALGARY, Alberta, Oct. 05, 2026 (GLOBE NEWSWIRE) — Canoe Financial is proud to announce a new sponsorship partnership with Canadian Olympic Gold Medallist and World Champion canoeist Katie Vincent, one of Canada’s most accomplished athletes and a leading figure in the sport of canoe sprint. The partnership will extend through the 2028 Olympic cycle and will feature a national marketing campaign built around the principles that define both Vincent’s athletic journey and Canoe Financial’s investment philosophy: Discipline compounds. Performance is earned.

As Canada’s premier canoe sprint athlete, Vincent has established herself among the world’s elite through years of dedication, preparation, and relentless commitment to excellence. Her career includes Olympic gold and bronze medals, world championship titles, and multiple world records, achievements built through a disciplined process long before race day.

The partnership reflects a natural alignment between Vincent’s approach to athletic performance and Canoe Financial’s approach to investing. Both recognize that success is rarely defined by a single moment. It is the result of a disciplined process, repeated consistently over time.

“Katie’s story is about more than winning medals,” said Darcy Hulston, President and Chief Executive Officer of Canoe Financial. “Her success is built on the same beliefs that guide our business every day. Driven by process. Discipline compounds. Performance is earned. Those beliefs are at the heart of everything we do for our investors, and Katie is an inspiring example of what can be achieved when you commit to them over the long term.”

The sponsorship also represents a uniquely authentic connection between Canoe Financial and the sport of canoeing. As Vincent competes on the world stage, Canoe Financial will support her journey while celebrating the values of perseverance, preparation, and excellence that resonate with Canadians from coast to coast.

About Canoe Financial
Canoe Financial is one of Canada’s fastest growing independent mutual fund companies managing nearly $25 billion in assets across a diversified range of award-winning investment solutions. Founded in 2008, Canoe Financial is an employee-owned investment management firm focused on building financial wealth for Canadians. Canoe Financial has a significant presence across Canada, including offices in Calgary, Toronto and Montreal.

Contact
Investor Relations
1–877–434–2796
info@canoefinancial.com

Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. Mutual funds are not guaranteed, their values change frequently and past performance may not be repeated.

Coop Pank AS (the Bank) announces that during the period 28.09.2026 – 04.10.2026, it has acquired the company’s own shares on the Nasdaq Tallinn Stock Exchange as follows:

Date	Aggregated volume (pcs)	Weighted average price per day (EUR)
28.09.2026	9,264	2.31000000
29.09.2026	9,264	2.30500000
30.09.2026	3,516	2.29000000
01.10.2026	2,742	2.30000000

Bank is acquiring its own shares based on the resolution of the company’s general meeting of shareholders held on 8 April 2026, and under the conditions decided by the Supervisory Board and Management Board. Summary data of the acquisitions will be disclosed no later than on the seventh trading day after the transaction and will be made available to the Financial Supervision and Resolution Authority, via the Nasdaq Tallinn system, and on Coop Bank´s investor website.

Additional information:
Paavo Truu
CFO
Phone: 5160 231
E-mail: paavo.truu@cooppank.ee

Coop Pank, based on Estonian capital, is one of the five universal banks operating in Estonia. The bank has 239,100 clients who use everyday banking services. Coop Pank uses the synergy created between retail trade and banking and brings everyday banking solutions closer to people. The majority shareholder of the Bank is a domestic retail chain Coop Eesti, the sales network of which comprises over 330 stores.

AS Tallinna Sadam (hereinafter Tallinna Sadam) and TT-Line GmbH (hereinafter TT-Line) have signed an agreement for the operation of a vessel on the Muuga (Estonia)–Vuosaari (Finland) route. The route will be served by a ro-pax ferry with around 2 000 freight lanemeters and a restaurant/café, a passenger lounge and other facilities for passengers and truckdrivers as well as cabins. The vessel used is intended to be announced in November. The vessel is expected to start operating on the route during the first quarter of 2027, with the exact launch date to be confirmed. 

The Muuga–Vuosaari ferry connection is of strategic importance for freight transport between Estonia and Finland. It provides logistics and transport companies with a fast maritime route and helps divert trucks and trailers away from the city centres of Tallinn and Helsinki. The connection supports the competitiveness of Estonia’s export-oriented economy by improving companies’ access to Finnish and, more broadly, Nordic markets. At the same time, it strengthens the position of Estonia and Muuga harbour as a key north-south transport and transit corridor, linking Finland to the Baltic states and, subsequently, to Central and Southern Europe.

The regular ferry route between the cargo harbours operated by the ports of Tallinn and Helsinki was launched in 2017 and has been served by both Tallink and Eckerö Line. Currently, the route is operated by Eckerö Line with the vessel Finbo Cargo.

“Freight volumes on the Muuga–Vuosaari route have grown steadily over the years and are now approaching the limits of what can be handled with a single vessel. This clearly demonstrates market demand for additional capacity and more frequent departures. The addition of a second operator will provide customers with greater choice and flexibility, strengthen the reliability of the connection and support further growth in trade between Estonia and Finland,” said Rene Pärt, Member of the Management Board of Tallinna Sadam.

The agreement will contribute to the port’s revenues through vessel call, cargo and passenger fees, while enabling more efficient use of existing infrastructure.

TT-Line is a family-owned shipping company established in 1962 in Germany.  Its fleet consists of 9 ro-pax vessels. The company’s core business is the transport of passengers, passenger vehicles and freight, connecting Germany,Sweden, Poland and Lithuania and serving routes that include the ports of Travemünde, Rostock, Trelleborg, Karlshamn, Świnoujście and Klaipėda.

Tallinna Sadam is one of the largest cargo- and passenger port complexes in the Baltic Sea region. In addition to passenger and freight services, Tallinna Sadam group also operates in shipping business via its subsidiaries – OÜ TS Laevad provides ferry services between the Estonian mainland and the largest islands, and OÜ TS Shipping charters its multifunctional vessel Botnica for icebreaking and offshore services in Estonia and projects abroad. Tallinna Sadam group is also a shareholder of an associate AS Green Marine, which provides waste management services.

Additional information:

Angelika Annus
Head of Investor Relations
Tel. +372 5649 6230
angelika.annus@ts.ee